Document is current
Any future updates will be listed below
-
Authors
Goodwin, Grace J.
Moeller, Stacey
Nguyen, Amy
Cummings, Jeffrey L.
John, Samantha E.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025, P20GM109025)
- License Information
-
More Information
Article History
Received: 24 April 2023
Accepted: 26 July 2023
First Online: 11 August 2023
Declarations
:
: Permission to utilize the de-identified data within the present manuscript is obtained through a data request to the National Alzheimer’s Coordinating Center (NACC:), which includes a Data Use Agreement. The present analyses were assigned approval and data access through NACC project #5789. Participants and study partners enrolled at each contributing Alzheimer’s disease Research Center provide written informed consent as part of the IRB-approved study protocol at that site. This consent covers both the data collection procedures required by the respective center as well as the inclusion of the participant’s data in the larger NACC database.
: Not applicable.
: JLC has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies.
